Overview

Oral Immunotherapy (OIT) for Peanut Allergy

Status:
Completed
Trial end date:
2016-12-12
Target enrollment:
Participant gender:
Summary
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill